Assessing variation among the drug-lists of 16 cities and impact on cardiovascular disease mortality: Evidence from Anhui

Anping Guo; Zhenzhen Pan; Haizhu Tan

doi:10.1016/j.ipha.2025.05.002

Intelligent Pharmacy ›› 2025, Vol. 3 ›› Issue (6) :371 -377. DOI: 10.1016/j.ipha.2025.05.002

Full length article

Assessing variation among the drug-lists of 16 cities and impact on cardiovascular disease mortality: Evidence from Anhui

Author information +

History +

PDF (2752KB)

Abstract

Background: This study compares the differences in city-level cardiovascular disease (CVD) drug-lists and investigates their relationship with CVD mortality rate across 16 cities in Anhui province, China.

Methods: Data on the usage of CVD medicines from 2016 to 2020 in hospitals across various levels in 16 cities and China's 2018 national list of essential medicines (EMs) were collected and mortality, demographic, environmental data related to CVD were analyzed. The negative binomial mixed-effects model was adopted to compare the differences. A generalized estimating equation was applied to evaluate associations between Anhui city-level drug-lists and mortality over the five years.

Results: The drug-lists across cities in Anhui province were short. Analysis revealed that the drug-lists of ten cities were shorter than that of the capital city, Hefei. Healthcare expenditure appeared to impact the length of druglists. After controlling for per capita GDP, population, widowhood rate, and beds per 1000 people, it was found that differences in drug-lists were associated with the CVD mortality rate in Anhui Province.

Keywords

Drug-list / Essential medicine / Cardiovascular diseases

Cite this article

Download citation ▾

Anping Guo, Zhenzhen Pan, Haizhu Tan. Assessing variation among the drug-lists of 16 cities and impact on cardiovascular disease mortality: Evidence from Anhui. Intelligent Pharmacy, 2025, 3(6): 371-377 DOI:10.1016/j.ipha.2025.05.002

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	World HO . World Health Organization Model List of Essential Medicines: 22nd List (2021). 2021.

[2]	Executive Board . WHO Medicines Strategy:Revised Procedure for Updating WHO's Model List of Essential Drugs: Report by the Secretariat. 2002.

[3]	Chow CK , Nguyen TN , Marschner S , et al. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Glob Health. 2020; 5 (11): e002640.

[4]	Wirtz VJ , Kaplan WA , Kwan GF , Laing RO . Access to medications for cardiovascular diseases in low-and middle-income countries. Circulation. 2016; 133 (21): 2076- 2085.

[5]	Taglione MS , Persaud N . Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study. BMJ Open. 2021; 11 (8): e045262.

[6]	Steiner L , Maraj D , Woods H , et al. A comparison of national essential medicines lists in the Americas. Rev Panam Salud Públic. 2020; 44: e5.

[7]	Steiner L , Fraser S , Maraj D , Persaud N . Associations between essential medicines and health outcomes for cardiovascular disease. BMC Cardiovasc Disord. 2021; 21 (1): 151.

[8]	Kinge JM , Modalsli JH , Overland S , et al. Association of household income with life expectancy and cause-specific mortality in Norway, 2005-2015. JAMA. 2019; 321 (19): 1916- 1925.

[9]	World HO . Working Together to Promote Cardiovascular Health. 2016.

[10]	Bazargani YT , Ewen M , de Boer A , Leufkens HGM , Mantel-Teeuwisse AK . Essential medicines are more available than other medicines around the globe. PLoS One. 2014; 9 (2): e87576.

[11]	Kishore SP , Blank E , Heller DJ , et al. Modernizing the world health organization list of essential medicines for preventing and controlling cardiovascular diseases. J Am Coll Cardiol. 2018; 71 (5): 564- 574.

[12]	Mehrtash H , Laing R , Wirtz VJ . Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region. East Mediterr Health J. 2018; 24 (5): 427- 434.

[13]	Bazargani YT , Ugurlu M , de Boer A , Leufkens HGM , Mantel-Teeuwisse AK . Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. BMC Cardiovasc Disord. 2018; 18 (1): 126.

[14]	Li X , Wu C , Lu J , et al. Cardiovascular risk factors in China: a nationwide populationbased cohort study. Lancet Public Health. 2020; 5 (12): e672- e681.

[15]	Zhang M , Zou K , Liu Z , et al. Availability of essential medicines, progress and regional distribution in China: a systematic review and meta-analysis. Front Public Health. 2023; 11: 1149838.

[16]	Tian X , Song Y , Zhang X . National Essential Medicines List and policy practice: a case study of China's health care reform. BMC Health Serv Res. 2012; 12: 401.

[17]	Twohig-Bennett C , Jones A . The health benefits of the great outdoors: a systematic review and meta-analysis of greenspace exposure and health outcomes. Environ Res. 2018; 166: 628- 637.

[18]	Zare Sakhvidi MJ , Yang J , Mehrparvar AH , et al. Exposure to greenspace and cancer incidence, prevalence, and mortality: a systematic review and meta-analyses. Sci Total Environ. 2022; 838 (Pt 2): 156180.

[19]	Fu W , Liu Y , Yan S , et al. The association of noise exposure with stroke incidence and mortality: a systematic review and dose-response meta-analysis of cohort studies. Environ Res. 2022; 215 (Pt 1): 114249.

[20]	Baptista EA , Queiroz BL . Spatial analysis of cardiovascular mortality and associated factors around the world. BMC Public Health. 2022; 22 (1): 1556.

[21]	Wang L , Yi Z . Marital status and all-cause mortality rate in older adults: a population-based prospective cohort study. BMC Geriatr. 2023; 23 (1): 214.

[22]	Dhindsa DS , Khambhati J , Schultz WM , Tahhan AS , Quyyumi AA . Marital status and outcomes in patients with cardiovascular disease. Trends Cardiovasc Med. 2020; 30 (4): 215- 220.

[23]	Tanno K , Ohsawa M , Itai K , et al. Associations of marital status with mortality from all causes and mortality from cardiovascular disease in Japanese haemodialysis patients. Nephrol Dial Transplant. 2013; 28 (4): 1013- 1020.

[24]	Kursa MB , Rudnicki WR . Feature selection with Boruta package. J Stat Software. 2010; 36 (11): 1- 13.

[25]	Friendly M . Visualizing Categorical Data. SAS Institute; 2000.

[26]	Chen C . Generalized additive mixed models. Commun Stat Theor Methods. 2000; 29: 1257- 1271.

[27]	Gelman A , Hill J . Data Analysis Using Regression and Multilevel/Hierarchical Models: Simulation of Probability Models and Statistical Inferences. 2006.

[28]	Bu R , Ková P , Lumley T . Longitudinal data analysis for generalized linear models with follow-up dependent on outcome-related variables. Can J Stat. 2007; 35 (4): 485- 500.

[29]	World HO . Equitable Access to Essential Medicines: A Framework for Collective Action. 2004.

[30]	Mahmic-Kaknjo M , Jelicic-Kadic A , Utrobicic A , et al. Essential medicines availability is still suboptimal in many countries: a scoping review. J Clin Epidemiol. 2018; 98: 41- 52.

[31]	Cheng L , Li C , Zhang X , Chen Y , Yan J . The consistency between the Chinese essential medicines list and treatment guidelines-taking oncology medicines as an example. Front Public Health. 2022; 10: 943994.

[32]	Persaud N , Jiang M , Shaikh R , et al. Comparison of essential medicines lists in 137 countries. Bull World Health Organ. 2019; 97 (6): 394- 404C.

[33]	Gaziano TA . Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa. Heart. 2008; 94 (2): 140- 144.

[34]	Jia Y , Hu M , Fu H , Yip W . Provincial variations in catastrophic health expenditure and medical impoverishment in China: a nationwide population-based study. Lancet Reg Health West Pac. 2023; 31: 100633.

[35]	Li Y , Ying C , Sufang G , et al. Evaluation, in three provinces, of the introduction and impact of China's National Essential Medicines Scheme. Bull World Health Organ. 2013; 91 (3): 184- 194.

[36]	Dhindsa DS , Khambhati J , Schultz WM , Tahhan AS , Quyyumi AA . Marital status and outcomes in patients with cardiovascular disease. Trends cardiovas Med. 2020; 30 (4): 215- 220.

[37]	Long RM , Terracciano A , Sutin AR , et al. Loneliness, social isolation, and living alone associations with mortality risk in individuals living with cardiovascular disease: a systematic review, meta-analysis, and meta-regression. Psychosom Med. 2023; 85 (1): 8- 17.

[38]	Steptoe A , Shankar A , Demakakos P , Wardle J . Social isolation, loneliness, and allcause mortality in older men and women. Proc Natl Acad Sci U S A. 2013; 110 (15): 5797- 5801.

[39]	Hassanin A , Hassanein M , Bendary A , Maksoud MA . Demographics, clinical characteristics, and outcomes among hospitalized heart failure patients across different regions of Egypt. Egypt Heart J. 2020; 72 (1): 49.